Lunai Bioworks (LNAI) Other Non-Current Assets (2012 - 2026)
Lunai Bioworks (LNAI) recorded quarterly Other Non-Current Assets of $32819.0 in Q1 2026, down 2.35% quarter-over-quarter from $33608.0 in Q4 2025, and down 99.97% on a YoY basis from $113.7 million in Q1 2025.
Lunai Bioworks (LNAI) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Lunai Bioworks' Other Non-Current Assets history runs 15 years deep, the most recent figure standing at $32819.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 99.97% year-over-year to $32819.0; the TTM figure through Mar 2026 stood at $32819.0 (down 99.97% YoY), while the FY2025 annual figure was $6.8 million, down 95.76% from the prior year.
- Other Non-Current Assets was $32819.0 for Q1 2026 at Lunai Bioworks, down from $33608.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $176.4 million in Q1 2024 to a low of $21741.0 in Q2 2023.
- Historically, Other Non-Current Assets has averaged $52.7 million across 5 years, with a median of $6.8 million in 2025.
- The sharpest annual moves came in 2024 and 2026: Other Non-Current Assets surged 738825.01% in 2024, then sank 99.97% in 2026.
- A 5-year view of Other Non-Current Assets shows it stood at $74.3 million in 2022, then plunged by 99.97% to $21742.0 in 2023, then surged by 502199.6% to $109.2 million in 2024, then tumbled by 99.97% to $33608.0 in 2025, then declined by 2.35% to $32819.0 in 2026.
- The last three Other Non-Current Assets figures came in at $32819.0 (Q1 2026), $33608.0 (Q4 2025), and $6.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Lunai Bioworks | 95.85 Mn | 92.70 Mn | 20,942.00 | 32,819.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32,819.00 |
| Dec 31, 2025 | 33,608.00 |
| Sep 30, 2025 | 6.15 Mn |
| Jun 30, 2025 | 6.82 Mn |
| Mar 31, 2025 | 113.66 Mn |
| Dec 31, 2024 | 109.21 Mn |
| Sep 30, 2024 | 119.43 Mn |
| Jun 30, 2024 | 160.65 Mn |
| Mar 31, 2024 | 176.38 Mn |
| Dec 31, 2023 | 21,742.00 |
| Sep 30, 2023 | 55.17 Mn |
| Jun 30, 2023 | 21,741.00 |
| Mar 31, 2023 | 58,586.00 |
| Dec 31, 2022 | 74.33 Mn |
| Sep 30, 2022 | 65,285.00 |
| Jun 30, 2022 | 74.48 Mn |
| Mar 31, 2022 | 21,742.00 |
| Dec 31, 2021 | 167.85 Mn |
| Sep 30, 2021 | 167.91 Mn |
| Jun 30, 2021 | 167.99 Mn |